NCT03902509View on ClinicalTrials.gov

A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

May 24, 2019

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions

Radiation-induced Lung Injury

Interventions

DRUG

Pirfenidone

pirfenidone capsule made in China

DRUG

basic treatment

glucocorticoid and expectant treatment etc.

Trial Locations (2)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Beijing Continent Pharmaceutical Co, Ltd.

INDUSTRY

NCT03902509 - A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. | Biotech Hunter | Biotech Hunter